Breviscapine alleviates NASH by inhibiting TGF‐β‐activated kinase 1‐dependent signaling

Abstract

Breviscapine prevents metabolic stress-induced NASH progression through direct inhibition of TAK1 signaling. Breviscapine might be a therapeutic candidate for the treatment of NASH.